OOIR: Observatory of International Research

Papers

(The H4-Index of Nature Reviews Rheumatology is 60. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-07-01 to 2025-07-01.)

Article	Citations
Inflammatory arthritis affects men’s fertility	559
SLC26A2 deficiency, matrix stiffness and mechanotransduction linked in osteoporosis	427
Bimekizumab effective across the axSpA spectrum	371
No benefit from adding MTX to ustekinumab	332
Targeting articular Mmp13 in OA	302
Low-dose rituximab can go even lower	284
Genome-wide mutagenesis reported in systemic sclerosis	268
Rheumatic diseases on the rise	241
A role for TGFβ and EBV in MIS-C pathogenesis	221
COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations	191
Biological and clinical roles of IL-18 in inflammatory diseases	181
New drug formulation reduces bone loss	180
FOXP3 splice variant is associated with autoimmune disease	170
Towards better management of sterile bone inflammation	163
Use of platelet-rich plasma for knee OA not supported by RCT results	156
MIS-C: myths have been debunked, but mysteries remain	155
Inflammation across tissues: can shared cell biology help design smarter trials?	149
Urchin-like nanoparticles for miRNA therapy of OA	148
2021 ACR guideline for JIA reflects changes in practice	136
The 2022 ACR vaccination guideline: a call-to-action	135
The value of comparative efficacy studies in informing rheumatology guidelines	125
Imbalance of threat and soothing systems in fibromyalgia: rephrasing an established mechanistic model?	115
To choose or not? The value of discrete-choice experiments in rheumatology	114
Down syndrome: insights into autoimmune mechanisms	108
Ageing stem cells hold the key to age-related bone degeneration	107

Appraising the evolving landscape of protease inhibition in osteoarthritis	106
Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician	100
Which NSAIDs are best for OA treatment?	99
Co-trimoxazole reduces mortality in anti-MDA5-DM	99
Low-dose glucocorticoids benefit seniors with RA	98
S100A4 inhibition targets fibrosis in SSc	90
Calprotectin tracks tocilizumab-treated RA	89
Wnt-induced IGF1 drives OA	88
Publisher Correction: Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician	88
Biologics in rheumatoid arthritis: a lifetime treatment or possibility of drug holidays?	88
Author Correction: Proposals for the rheumatological use of JAK inhibitors	85
Guiding ILD management in systemic autoimmune rheumatic diseases	84
A direct link between SARS-CoV-2 and bone loss	82
Rheumatic diseases and metabolism: where centre and periphery meet	79
Fumarate drives interferon release in systemic sclerosis monocytes	79
Low back pain is a growing concern	78
Sexual dimorphism in the prevalence, manifestation and outcomes of axial spondyloarthritis	77
Rheumatology in the digital health era: status quo and quo vadis?	76
Distinct mucosal endotypes as initiators and drivers of rheumatoid arthritis	76
sCD13 role in arthritis mediated via bradykinin receptor	74
Antibiotics keep rheumatic heart disease at bay	73
Erosive cargo from synovial fibroblasts	71
Targeting the IVD clock to halt degeneration	71
Which DMARD for ICI-associated arthritis?	68
Publisher Correction: Recent advances in the diagnosis and management of neuropsychiatric lupus	67
Macrophage-coated nanocarriers for gouty arthritis	67
ERAP1 and the return of the UPR in ankylosing spondylitis	66
Chimeric receptors broaden the therapeutic landscape for autoimmune disease	65
Insights into IVDD pathogenesis in 2024	64
CAR T cells induce drug-free SLE remission	64
PGE2 receptor antagonist has potential to treat osteoarthritis	64
A path towards personalized medicine for autoinflammatory and related diseases	63
International Guideline for Idiopathic Inflammatory Myopathy-Associated Cancer Screening: an International Myositis Assessment and Clinical Studies Group (IMACS) initiative	62
Antibodies induce fibromyalgia symptoms	61
Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach	61
Blocking CDK7 attenuates inflammatory arthritis	60